Dilaudid (hydromorphone) is stronger than morphine on a milligram-for-milligram basis. When taken by mouth, hydromorphone is roughly 5 times more potent than morphine, meaning 1 mg of hydromorphone provides about the same pain relief as 5 mg of morphine. When given intravenously, the gap widens: 1 mg of IV hydromorphone is equivalent to about 18 mg of oral morphine, compared to just 3 mg of oral morphine for 1 mg of IV morphine.
How Much Stronger Dilaudid Actually Is
The standard way to compare opioid strength is by converting everything into oral morphine equivalents. Using conversion factors from UCSF Health and the CDC:
- Oral morphine: 1 mg equals 1 morphine milligram equivalent (MME)
- Oral hydromorphone: 1 mg equals 5 MME
- IV morphine: 1 mg equals 3 MME
- IV hydromorphone: 1 mg equals 18 MME
So if you’re comparing pills, Dilaudid is about 5 times stronger. If you’re comparing IV doses, Dilaudid is about 6 times stronger than morphine (18 MME vs. 3 MME per milligram). This is why Dilaudid is prescribed in much smaller doses. A typical starting dose of oral morphine might be 5 to 10 mg, while an equivalent Dilaudid dose would be only 1 to 2 mg.
Why Dilaudid Is More Potent
Two things explain the potency difference. First, hydromorphone binds more tightly to the brain’s primary pain-relief receptors. Lab measurements of binding affinity show hydromorphone latches on about 3 times more strongly than morphine. Second, hydromorphone crosses from the bloodstream into the brain more easily. Its chemical structure makes it roughly twice as fat-soluble as morphine, which helps it pass through the blood-brain barrier faster and in greater concentrations. The combination of tighter binding and better brain penetration is what makes it 5 to 8 times more potent overall, depending on the route.
Stronger Does Not Mean More Effective
A common misconception is that “stronger” means “works better for pain.” It doesn’t. When doses are adjusted to be equivalent, both drugs provide similar levels of pain relief. A systematic review of hydromorphone studies found little difference between the two in terms of how well they control pain, how often they cause side effects, or how patients rate their experience. Morphine remains the traditional first-line opioid for severe pain, particularly in cancer care. Hydromorphone is typically recommended as an alternative when someone doesn’t get enough relief from morphine or has trouble tolerating its side effects.
How They Feel and How Long They Last
When given intravenously, both drugs kick in within 5 to 10 minutes and reach peak effect in about 30 to 60 minutes. The main timing difference is duration: morphine’s effects last roughly 3 to 6 hours, while hydromorphone tends to wear off a bit sooner, in the range of 3 to 5 hours. In practice, this means hydromorphone may need to be taken slightly more often for around-the-clock pain control.
Differences in Side Effects
Both drugs share the standard opioid side effects: nausea, constipation, drowsiness, and slowed breathing at high doses. One area where they may differ is itching. Morphine is more commonly associated with skin itching, sometimes severe enough that antihistamines don’t help. In these cases, switching to hydromorphone often resolves the problem. Whether this is caused by histamine release, a direct receptor effect, or an individual reaction to morphine specifically isn’t fully settled, but the clinical pattern is well recognized.
Why the Numbers Aren’t Exact
Every conversion ratio you see is an estimate. The CDC’s 2022 prescribing guideline emphasizes that equianalgesic conversions “cannot account for individual variability in genetics and pharmacokinetics.” People metabolize these drugs differently based on liver function, kidney function, genetics, age, and how long they’ve been taking opioids. This is why clinicians don’t simply do the math and swap one drug for the other at the “equivalent” dose. When switching between opioids, the new drug is typically started at a lower dose than the calculated equivalent and adjusted upward, specifically to avoid overdose from incomplete cross-tolerance.
UCSF’s own conversion table carries a direct warning: opioid equivalence tables should not be used as a direct conversion tool. They’re designed to express relative potency, not to dictate prescribing. The 5-to-1 oral ratio is a useful benchmark for understanding how the two drugs compare, but real-world dosing involves clinical judgment beyond simple arithmetic.